At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...

As the first public database to provide detailed comparable information on the microstructure of trade flows between countries, the Exporter Dynamics Database (EDD) has filled a significant gap in our ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Elise Czajkowski Elise Czajkowski is a writer on the sleep team. She’s been ...